Overview

Coherus BioSciences develops and sells biosimilars, which are highly similar versions of approved biologic medicines used to treat various diseases. These biosimilars are designed to be as effective and safe as the original products but are offered at a lower cost, making them more affordable for patients and healthcare systems. Coherus focuses on the research, development, and commercialization of these products, ensuring they meet high quality and efficacy standards set by regulatory authorities. The company aims to improve patient lives by expanding access to essential biologic treatments, thereby helping to offset rising healthcare costs. Coherus serves a diverse range of clients, including healthcare providers and hospitals, and generates revenue through the sale of its biosimilar products, which provide a cost-effective alternative in the biopharmaceutical market.

💡 Want to apply to Coherus BioSciences?

You have ways to get a Coherus BioSciences referral from your network.

Get referrals →

Simplify's Take

What believers are saying

• Increased focus on immuno-oncology could open new revenue streams for Coherus.
• The Udenyca wearable injector device may capture a larger share of the pegfilgrastim market.
• Collaboration with the Cancer Research Institute highlights commitment to innovative cancer treatments.

What critics are saying

• 30% staff reduction may impact operational efficiency and employee morale.
• Exit from biosimilar space could lead to strategic uncertainty and market share loss.
• High-risk clinical trials in collaboration with Cancer Research Institute may not succeed.

What makes Coherus BioSciences unique

• Coherus focuses on developing cost-effective biosimilars for oncology and inflammatory diseases.
• The company emphasizes high-quality biologic medicines to improve healthcare accessibility.
• Coherus is committed to innovative cancer treatments, enhancing its reputation in oncology.

Help us improve and share your feedback! Did you find this helpful?

YesNo